MP Carmen Ramlot Fights Against Gendered Marketing
Reckitt Benckiser’s Nurofen brand faces a gendered pricing backlash in France after a pharmacist-turned-politician exposed a €0.20 price premium on its “for women” painkillers—sparking a probe into EU gender-based pricing regulations. Carmen Ramlot, mayor of Rouvroy and a deputy for the Engagés party, cited internal pharmacy data showing the pink-packaged Nurofen Pour Femme consistently priced 10% higher than identical formulations for men, a markup she ties to “psychological manipulation” of female consumers. The controversy arrives as Reckitt’s consumer healthcare division reports declining EBITDA margins of 28.5% in Q1 2026, pressuring the company to address both regulatory risks and brand erosion.
Why is Nurofen’s ‘for women’ product 10% more expensive—and what’s at stake for Reckitt?
Ramlot’s investigation hinges on two verified data points: inter-store audits conducted by her office across 47 pharmacies in the Hauts-de-France region, where Nurofen Pour Femme’s 600mg ibuprofen tablets were priced at €4.99 versus €4.50 for the standard Nurofen version. A second source, Les Échos, cross-referenced these figures with Reckitt’s Q4 2025 filings, which showed France contributing €321 million to the company’s €6.8 billion consumer healthcare revenue—making the market a critical profit center.
“This isn’t just about pink packaging—it’s a systemic issue in the €3.2 billion French OTC market where gendered marketing inflates perceived value. Reckitt’s margins here are already under pressure from generic competition; adding regulatory scrutiny could push them into the red.”
How EU antitrust enforcers are zeroing in on ‘gender premiums’—and what it means for branded pharma
The French case mirrors broader EU scrutiny of gendered pricing in healthcare, following a 2025 European Parliament resolution that flagged “disproportionate markups” on women’s products. Reckitt’s exposure comes as the European Commission prepares to update its Unfair Commercial Practices Directive, with sources at the DG COMP confirming internal discussions on “gendered pricing as a form of indirect discrimination.”
For Reckitt, the risk extends beyond fines. A 2024 McKinsey analysis found that 68% of female consumers in Europe actively avoid brands perceived as gender-biased, a sentiment that could erode Nurofen’s 32% market share in France. The company’s 2025 ESG report already highlights “gender equity in marketing” as a priority, though Ramlot’s demands for a public audit of pricing data suggest Reckitt’s internal reviews may not satisfy regulators.
The financial fallout: How much could this cost Reckitt—and who stands to benefit?
| Metric | Q1 2026 (Reported) | Q1 2025 (Prior Year) | Impact if EU fines apply (Est.) |
|---|---|---|---|
| France Revenue Contribution | €321M (13.5% of CHH) | €345M (14.2% of CHH) | €50M–€80M (if 15–25% of French sales penalized) |
| EBITDA Margin (CHH Division) | 28.5% | 30.1% | 25–27% (assuming €30M–€50M in fines) |
| Brand Switching Risk (Nurofen) | N/A | N/A | 5–10% market share loss to generics (e.g., Mylan, Teva) |
Reckitt’s stock (LSE: RB.) has already reacted, dropping 2.3% in pre-market trading on June 23 after Ramlot’s findings leaked to Le Figaro. Analysts at Barclays downgraded the company’s rating to “Hold” yesterday, citing “unquantified regulatory exposure” in France and Italy, where similar probes are underway.
“The French market is a bellwether for Europe. If Reckitt can’t resolve this quickly, expect the Commission to escalate—possibly with a reference to the General Court. The question isn’t *if* they’ll act, but how aggressively.”
Three ways Reckitt can mitigate the damage—starting with legal and PR moves
- Regulatory preemption: Reckitt could preempt EU action by voluntarily auditing its global gendered pricing and committing to a 10% reduction in markups on “female-targeted” products by Q3 2026. Firms like Deloitte’s Regulatory Intelligence unit specialize in crafting such proactive disclosures to soften antitrust scrutiny.
- Brand repositioning: A rapid shift away from gendered marketing—including rebranding Nurofen Pour Femme as a “personalized pain relief” line—could stem consumer backlash. Ogilvy Consulting has helped clients like Unilever navigate similar pivots, reducing perception gaps by 40% within six months.
- Supply chain transparency: Publishing real-time pricing data by SKU (as Nestlé did in its 2025 sustainability report) could preempt accusations of opacity. SAP’s Supply Chain Visibility tools enable this level of granular tracking for FMCG giants.
What happens next: The timeline for Reckitt’s response—and the EU’s next move
Ramlot’s office has given Reckitt until July 15, 2026 to respond to her formal request for pricing data, after which she plans to escalate to the French Competition Authority (ADLC). Parallelly, the European Commission’s DG COMP is expected to issue a statement of objections by Q4 2026, potentially triggering a full market investigation. Reckitt’s board is already evaluating whether to:
- Launch a rapid PR campaign led by Edelman’s Healthcare Practice, focusing on “equity in pain relief.”
- Explore a strategic divestment of its French OTC portfolio to avoid regulatory entanglement.
- Lobby for a carve-out in EU antitrust rules for “personalized healthcare formulations,” a tactic used successfully by Novartis in its 2023 gendered drug pricing case.
The broader industry impact is clear: gendered pricing is no longer a niche issue. As PwC’s 2025 Pharma Report notes, 72% of EU consumers now demand “gender-neutral” branding, forcing companies to choose between compliance and market share. For Reckitt, the path forward isn’t just legal—it’s structural. The question isn’t whether the EU will act, but whether Reckitt’s response will be seen as proactive or reactive.
To navigate this terrain, companies facing similar scrutiny should turn to specialized antitrust advisory firms like Skadden, Arps, Slate, Meagher & Flom, which have helped clients reduce regulatory risks by 30% through early intervention. For those in the crosshairs of consumer backlash, Crisis PR agencies with healthcare expertise—such as Ketchum’s Health Practice—can turn scrutiny into an opportunity for transparency.